NasdaqGS - Nasdaq Real Time Price • USD
Royalty Pharma plc (RPRX)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 6:07 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 7 | 7 |
| Avg. Estimate | 0.99 | 0.96 | 3.8 | 4.14 |
| Low Estimate | 0.91 | 0.9 | 2.97 | 2.8 |
| High Estimate | 1.07 | 0.99 | 4.19 | 4.74 |
| Year Ago EPS | 1.6 | 0.84 | 4.5 | 3.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 6 | 6 |
| Avg. Estimate | 663.22M | 607.72M | 2.6B | 2.85B |
| Low Estimate | 524.53M | 544.47M | 2.28B | 2.46B |
| High Estimate | 731.45M | 681.01M | 2.79B | 3.23B |
| Year Ago Sales | 852.9M | -- | 2.35B | 2.6B |
| Sales Growth (year/est) | -22.20% | -- | 10.50% | 9.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.27 | 0.81 | 0.76 | 1.01 |
| EPS Actual | 1.6 | 0.84 | 0.79 | 1.15 |
| Difference | 0.33 | 0.03 | 0.03 | 0.14 |
| Surprise % | 26.00% | 3.70% | 3.90% | 13.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.99 | 0.96 | 3.8 | 4.14 |
| 7 Days Ago | 0.95 | 0.92 | 3.77 | 4.12 |
| 30 Days Ago | 0.95 | 0.92 | 3.77 | 4.12 |
| 60 Days Ago | 0.88 | 0.87 | 3.69 | 4.11 |
| 90 Days Ago | 0.93 | 0.94 | 3.83 | 4.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RPRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -38.10% | -- | -- | 1.60% |
| Next Qtr. | 14.30% | -- | -- | 10.50% |
| Current Year | -15.60% | -- | -- | 5.20% |
| Next Year | 8.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 3.20% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 41.66% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | B of A Securities: Buy to Buy | 4/12/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/20/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 2/20/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 11/9/2023 |
| Maintains | Morgan Stanley: Overweight to Overweight | 10/11/2023 |
| Maintains | Morgan Stanley: Overweight to Overweight | 8/9/2023 |
Related Tickers
ASMB Assembly Biosciences, Inc.
13.41
+0.60%
BBIO BridgeBio Pharma, Inc.
24.74
-0.84%
ROIV Roivant Sciences Ltd.
10.46
+0.97%
CYTK Cytokinetics, Incorporated
67.55
+0.82%
IMVT Immunovant, Inc.
28.22
-0.35%
INCY Incyte Corporation
52.35
-0.89%
CLRB Cellectar Biosciences, Inc.
3.0300
-0.33%
LEGN Legend Biotech Corporation
46.19
-1.97%
ALNY Alnylam Pharmaceuticals, Inc.
144.41
-0.52%
BPMC Blueprint Medicines Corporation
86.85
-2.31%